RE:RE:RE:RE:Only a corporate suit could call this merger a synergy...Yes, OttawaPeter, Bioasis is preclinical. Barely so, I think. But xB3-001 was described in October 2020 as being beyond preclinical.
I was looking at the history of xB3-002 (glioblastoma) earlier, looking for how Bioasis has described its payload in the corporate presentations.
The Gantt charts are interesting. In the October 2020 corporate presentation, 3 or 4 months after the Chiesi deal, Rathjen presented xB3-001 on the chart as beyond preclinical and into an "IND enabling" phase with Phase 1 clinical trials scheduled for Q1, 2022, a year ago.
Within the year, by late 2021, everything started disappearing, including xB3-001.
What we don't know is how advanced any preclinical work might be with the partners, Chiesi, J&J, etc.
It all gives me the creeps.
jd